Abadie, A. and Gardeazabal, J. (2003). ‘The Economic Costs of Conflict: a Case Study of the Basque Country’, American Economic Review, Vol. 93, pp. 113–132.
Adhvaryu, A., Fenske, J. and Nyshadham, A. (2014). Early Life Circumstance and Adult Mental Health, University of Oxford Department of Economics Discussion Paper Series No. 1471–0498.
Alpert, A., Evans, W. N., Lieber, E. M. and Powell, D. (2022). ‘Origins of the opioid crisis and its enduring impacts’, The Quarterly Journal of Economics, Vol. 137, pp. 1139–1179.
Alpert, A., Powell, D. and Pacula, R. L. (2018). ‘Supply‐side drug policy in the presence of substitutes: evidence from the introduction of abuse‐deterrent opioids’, American Economic Journal: Economic Policy, Vol. 10, pp. 1–35.
Altonji, J. G., Elder, T. E. and Taber, C. R. (2005). ‘Selection on observed and unobserved variables: assessing the effectiveness of catholic schools’, Journal of Political Economy, Vol. 113, pp. 151–184.
- Arteaga, C. and Barone, V. (2022). A Manufactured Tragedy: The Origins and Deep Ripples of the Opioid Epidemic, Mimeo.
Paper not yet in RePEc: Add citation now
Bazzi, S. and Blattman, C. (2014). ‘Economic shocks and conflict: evidence from commodity prices’, American Economic Journal: Macroeconomics, Vol. 6, pp. 1–38.
Beach, B. and Hanlon, W. W. (2018). ‘Coal smoke and mortality in an early industrial economy’, The Economic Journal, Vol. 128, pp. 2652–2675.
Berman, N. and Couttenier, M. (2015). ‘External shocks, internal shots: the geography of civil conflicts’, Review of Economics and Statistics, Vol. 97, pp. 758–776.
Berman, N., Couttenier, M., Rohner, D. and Thoenig, M. (2017). ‘This mine is mine! how minerals fuel conflicts in Africa’, American Economic Review, Vol. 107, pp. 1564–1610.
Berndt, E. R. (2002). ‘Pharmaceuticals in U.S. health care: determinants of quantity and price’, Journal of Economic Perspectives, Vol. 16, pp. 45–66.
Berndt, E. R., Bui, L., Reiley, D. R. and Urban, G. L. (1995). ‘Information, marketing, and pricing in the US antiulcer drug market’, The American Economic Review, Vol. 85, pp. 100–105.
- Brady, J. E., Wunsch, H., DiMaggio, C., Lang, B. H., Giglio, J. and Li, G. (2014). ‘Prescription drug monitoring and dispensing of prescription opioids’, Public Health Reports, Vol. 129, pp. 139–147.
Paper not yet in RePEc: Add citation now
Brückner, M. and Ciccone, A. (2010). ‘International commodity prices, growth and the outbreak of Civil War in Sub‐Saharan Africa’, The Economic Journal, Vol. 120, pp. 519–534.
Brückner, M. and Gradstein, M. (2013). ‘Exogenous volatility and the size of government in developing countries’, Journal of Development Economics, Vol. 105, pp. 254–266.
Brückner, M., Ciccone, A. and Tesei, A. (2012). ‘Oil price shocks, income, and democracy’, The Review of Economics and Statistics, Vol. 94, pp. 389–399.
- Campbell, E. G., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D. and Blumenthal, D. (2007). ‘A national survey of physician–industry relationships’, New England Journal of Medicine, Vol. 356, pp. 1742–1750.
Paper not yet in RePEc: Add citation now
Carpenter, C. S., McClellan, C. B. and Rees, D. I. (2017). ‘Economic conditions, illicit drug use, and substance use disorders in the United States’, Journal of Health Economics, Vol. 52, pp. 63–73.
- Case, A. and Deaton, A. (2015). ‘Rising morbidity and mortality in midlife among white non‐Hispanic Americans in the 21st century’, Proceedings of the National Academy of Sciences, Vol. 112, pp. 15078–15083.
Paper not yet in RePEc: Add citation now
- Case, A. and Deaton, A. (2018). Deaths of Despair Redux: a Response to Christopher Ruhm, Mimeo.
Paper not yet in RePEc: Add citation now
- Cegedim. (2013). 2012 U.S. Pharmaceutical Company Promotion Spending, Technical Report.
Paper not yet in RePEc: Add citation now
- Centers for Disease Control and Prevention. (2017). Annual Surveillance Drug‐Related Risks and Outcomes, Technical Report.
Paper not yet in RePEc: Add citation now
- Chen, L. H., Hedegaard, H. and Warner, M. (2014). ‘Drug‐poisoning deaths involving opioid analgesics: United States, 1999‐2011’, National Center for Health Statistics Data Brief, Vol. 166, pp. 1–8.
Paper not yet in RePEc: Add citation now
Currie, J., Jin, J. Y. and Schnell, M. (2019). ‘US employment and opioids: is there a connection?’, Research in Labor Economics, Vol. 47, pp. 253–280.
Currie, J., Lin, W. and Meng, J. (2014). ‘Addressing antibiotic abuse in China: an experimental audit study’, Journal of Development Economics, Vol. 110, pp. 39–51.
Currie, J., Lin, W. and Zhang, W. (2011). ‘Patient knowledge and antibiotic abuse: evidence from an audit study in China’, Journal of Health Economics, Vol. 30, pp. 933–949.
Cutler, D. M. and Glaeser, E. L. (2021). ‘When innovation goes wrong: technological regress and the opioid epidemic’, Journal of Economic Perspectives, Vol. 35, pp. 171–196.
Cutler, D., Skinner, J. S., Stern, A. D. and Wennberg, D. (2019). ‘Physician beliefs and patient preferences: a new look at regional variation in health care spending’, American Economic Journal: Economic Policy, Vol. 11, pp. 192–221.
- Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher‐Bartelson, B. and Green, J. L. (2015). ‘Trends in opioid analgesic abuse and mortality in the United States’, New England Journal of Medicine, Vol. 372, pp. 241–248.
Paper not yet in RePEc: Add citation now
- Datta, A. and Dave, D. (2017). ‘Effects of physician‐directed pharmaceutical promotion on prescription behaviors: longitudinal evidence’, Health Economics, Vol. 26, pp. 450–468.
Paper not yet in RePEc: Add citation now
Dave, D. and Saffer, H. (2012). ‘Impact of direct‐to‐consumer advertising on pharmaceutical prices and demand’, Southern Economic Journal, Vol. 79, pp. 97–126.
David, G., Markowitz, S. and Richards‐Shubik, S. (2010). ‘The effects of pharmaceutical marketing and promotion on adverse drug events and regulation’, American Economic Journal: Economic Policy, Vol. 2, pp. 1–25.
- DEA. (1992). Opium Poppy Cultivation and Heroin Processing in Southeast Asia, US Department of Justice: Drug Enforcement Administration Technical Report No. 141189.
Paper not yet in RePEc: Add citation now
- DOJ. (2008). Authorized Sources of Narcotic Raw Materials, Technical Report No. 25, Department of Justice.
Paper not yet in RePEc: Add citation now
- Doleac, J. L. and Mukherjee, A. (2022). ‘The moral hazard of lifesaving innovations: naloxone access, opioid abuse, and crime’, The Journal of Law and Economics, Vol. 65, pp. 211–238.
Paper not yet in RePEc: Add citation now
- Dorfman, R. and Steiner, P. O. (1954). ‘Optimal advertising and optimal quality’, The American Economic Review, Vol. 44, pp. 826–836.
Paper not yet in RePEc: Add citation now
Dube, O. and Vargas, J. F. (2013). ‘Commodity price shocks and civil conflict: evidence from Colombia’, The Review of Economic Studies, Vol. 80, pp. 1384–1421.
Evans, W. N., Lieber, E. M. and Power, P. (2019). ‘How the reformulation of oxycontin ignited the heroin epidemic’, Review of Economics and Statistics, Vol. 101, pp. 1–15.
- Fox, E. R., Birt, A., James, K. B., Kokko, H., Salverson, S. and Soflin, D. L. (2009). ‘ASHP guidelines on managing drug product shortages in hospitals and health systems’, American Journal of Health‐System Pharmacy, Vol. 66, pp. 1399–1406.
Paper not yet in RePEc: Add citation now
- Gammaitoni, A. R., Fine, P., Alvarez, N., McPherson, M. L. and Bergmark, S. (2003). ‘Clinical application of opioid equianalgesic data’, The Clinical Journal of Pain, Vol. 19, pp. 286–297.
Paper not yet in RePEc: Add citation now
- General Accounting Office. (2003). Prescription drugs: oxycontin abuse and diversion and efforts to address the problem, Technical Report.
Paper not yet in RePEc: Add citation now
- Gihleb, R., Giuntella, O. and Zhang, N. (2022). ‘The effect of mandatory‐access prescription drug monitoring programs on foster care admissions’, Journal of Human Resources, Vol. 57, pp. 217–240.
Paper not yet in RePEc: Add citation now
- Hadland, S. E., Rivera‐Aguirre, A., Marshall, B. D. and Cerdá, M. (2019). ‘Association of pharmaceutical industry marketing of opioid products with mortality from opioid‐related overdoses’, JAMA Network Open, Vol. 2, pp. 1–12.
Paper not yet in RePEc: Add citation now
Harris, M. C., Kessler, L. M., Murray, M. N. and Glenn, M. E. (2020). ‘Prescription opioids and labor market pains: the effect of schedule II opioids on labor force participation and unemployment’, Journal of Human Resources, Vol. 55, pp. 1319–1364.
Helland, E., Lakdawalla, D., Malani, A. and Seabury, S. A. (2020). ‘Unintended consequences of products liability: evidence from the pharmaceutical market’, The Journal of Law, Economics, and Organization, Vol. 36, pp. 598–632.
- Hollon, M. F. (2005). ‘Direct‐to‐consumer advertising: a haphazard approach to health promotion’, JAMA: Journal of the American Medical Association, Vol. 293, pp. 2030–2033.
Paper not yet in RePEc: Add citation now
- Horwitz, J. R., Davis, C., McClelland, L., Fordon, R. and Meara, E. (2021). ‘The importance of data source in prescription drug monitoring program research’, Health Services Research, Vol. 56, pp. 268–274.
Paper not yet in RePEc: Add citation now
Iizuka, T. (2007). ‘Experts' agency problems: evidence from the prescription drug market in Japan’, The Rand Journal of Economics, Vol. 38, pp. 844–862.
Iizuka, T. (2012). ‘Physician agency and adoption of generic pharmaceuticals’, American Economic Review, Vol. 102, pp. 2826–2858.
Iizuka, T. and Jin, G. Z. (2005). ‘The Effect of prescription drug advertising on doctor visits’, Journal of Economics & Management Strategy, Vol. 14, pp. 701–727.
Iizuka, T. and Jin, G. Z. (2007). ‘Direct to consumer advertising and prescription choice’, The Journal of Industrial Economics, Vol. 55, pp. 771.
- Jenks, S. (2011). ‘Efforts underway to curb drug shortages’, Journal of the National Cancer Institute, Vol. 103, pp. 914–915.
Paper not yet in RePEc: Add citation now
- Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W. and Alexander, G. C. (2014). ‘The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction’, Annual Review of Public Health, Vol. 36, pp. 559–574.
Paper not yet in RePEc: Add citation now
Kornfield, R., Donohue, J., Berndt, E. R. and Alexander, G. C. (2013). ‘Promotion of prescription drugs to consumers and providers, 2001–2010’, PLoS ONE, Vol. 8, e55504.
- Krueger, A. (2017). ‘Where have all the workers gone: an inquiry into the decline of the U.S. labor force participation rate’, Brookings Papers on Economic Activity. Vol. Fall 2017, pp. 1‐87.
Paper not yet in RePEc: Add citation now
- Leukefeld, C., Walker, R., Havens, J., Leedham, C. A. and Tolbert, V. (2007). ‘What does the community say: key informant perceptions of rural prescription drug use’, Journal of Drug Issues, Vol. 37, pp. 503–524.
Paper not yet in RePEc: Add citation now
Lind, J. T., Moene, K. O. and Willumsen, F. (2014). ‘Opium for the masses? Conflict‐induced narcotics production in Afghanistan’, The Review of Economics and Statistics, Vol. 96, pp. 949–966.
- Ling, D. C., Berndt, E. R. and Kyle, M. K. (2002). ‘Deregulating direct‐to‐consumer marketing of prescription drugs: effects on prescription and over‐the‐counter product sales’, The Journal of Law and Economics, Vol. 45, pp. 691–723.
Paper not yet in RePEc: Add citation now
Liu, Y.‐M., Yang, Y.‐H. K. and Hsieh, C.‐R. (2009). ‘Financial incentives and physicians' prescription decisions on the choice between brand‐name and generic drugs: evidence from Taiwan’, Journal of Health Economics, Vol. 28, pp. 341–349.
Lu, F. (2014). ‘Insurance coverage and agency problems in doctor prescriptions: evidence from a field experiment in China’, Journal of Development Economics, Vol. 106, pp. 156–167.
- Maclean, J. C., J. Mallatt, C. J. Ruhm, and K. I. Simon (2022): The Opioid Crisis, Health, Healthcare, and Crime: A Review of Quasi‐Experimental Economic Studies, NBER Working Paper Series No. WP 29983.
Paper not yet in RePEc: Add citation now
- Maclean, J. C., Mallatt, J., Ruhm, C. J. and Simon, K. I. (2021). ‘Economic studies on the opioid crisis: costs, causes, and policy responses’, in Oxford Research Encyclopedia of Economics and Finance, Oxford University Press.
Paper not yet in RePEc: Add citation now
- Mallatt, J. (2017). The Effect of Prescription Drug Monitoring Programs on Opioid Prescriptions and Heroin Crime Rates, Mimeo.
Paper not yet in RePEc: Add citation now
- Max, M. B., Donovan, M., Miaskowski, C. A., Ward, S. E., Gordon, D., Bookbinder, M., Cleeland, C. S., Coyle, N., Kiss, M., Thaler, H. T., et al. (1995). ‘Quality improvement guidelines for the treatment of acute pain and cancer pain’, JAMA, Vol. 274, pp. 1874–1880.
Paper not yet in RePEc: Add citation now
- Meinhofer, A. (2017). The War on Drugs: Estimating the Effect of Prescription Drug Supply‐Side Interventions, Mimeo.
Paper not yet in RePEc: Add citation now
- Metcalf, G. E. and Q. Wang (2019): Abandoned by Coal, Swallowed by Opioids? NBER Working Paper Series No. WP 26551.
Paper not yet in RePEc: Add citation now
Meyerhoefer, C. D. and Zuvekas, S. H. (2008). ‘The shape of demand: what does it tell us about direct‐to‐consumer marketing of antidepressants?’, The B.E. Journal of Economic Analysis & Policy,Vol. 8, Article 4.
- Mizik, N. and Jacobson, R. (2004). ‘Are physicians “easy marks”? quantifying the effects of detailing and sampling on new prescriptions’, Management Science, Vol. 50, pp. 1704–1715.
Paper not yet in RePEc: Add citation now
- Morton, F. S. and Kyle, M. (2011). ‘Markets for Pharmaceutical Products’, Handbook of Health Economics, Vol. 2, pp. 763–823.
Paper not yet in RePEc: Add citation now
- Nguyen, T. D., Bradford, W. D. and Simon, K. I. (2019b). ‘Pharmaceutical payments to physicians may increase prescribing for opioids’, Addiction, Vol. 114, pp. 1051–1059.
Paper not yet in RePEc: Add citation now
- Nguyen, T. D., W. D. Bradford, and K. I. Simon (2019a): How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs, NBER Working Paper Series No. 26356.
Paper not yet in RePEc: Add citation now
- Office on Drugs and CrimeUNODC (2007): World Drug Report 2007, Technical Report, United Nations.
Paper not yet in RePEc: Add citation now
- Okie, S. (2010). ‘A flood of opioids, a rising tide of deaths’, New England Journal of Medicine, Vol. 363, pp. 1981–1985.
Paper not yet in RePEc: Add citation now
- Outterson, K. (2005). ‘Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets’, Yale Journal of Health Policy, Law & Ethics, Vol. 193, pp. 193–291.
Paper not yet in RePEc: Add citation now
- Paoli, L., Greenfield, V. A., Charles, M. and Reuter, P. (2009). ‘The global diversion of pharmaceutical drugs. India: the third largest illicit opium producer?’, Addiction, Vol. 104, pp. 347–354.
Paper not yet in RePEc: Add citation now
- Patrick, S. W., Schumacher, R. E., Benneyworth, B. D., Krans, E. E., McAllister, J. M. and Davis, M. M. (2012). ‘Neonatal abstinence syndrome and associated health care expenditures: United States, 2000‐2009’, Journal of American Medical Association, Vol. 307, pp. 1934–1940.
Paper not yet in RePEc: Add citation now
- Paulozzi, L. J. (2012). ‘Prescription drug overdoses: a review’, Journal of Safety Research, Vol. 43, pp. 283–289.
Paper not yet in RePEc: Add citation now
- Paulozzi, L. J., Kilbourne, E. M. and Desai, H. A. (2011). ‘Prescription drug monitoring programs and death rates from drug overdose’, Pain Medicine, Vol. 12, pp. 747–754.
Paper not yet in RePEc: Add citation now
- Pollack, H. A. (2016). ‘Commentary on the economic burden of prescription opioid overdose, abuse, and dependence’, Medical Care, Vol. 54, pp. 899–900.
Paper not yet in RePEc: Add citation now
- Price, W. N. (2014). ‘Making do in making drugs: innovation policy and pharmaceutical manufacturing’, Boston College Law Review, Vol. 55, pp. 491–562.
Paper not yet in RePEc: Add citation now
- Rice, T. H. (1983). ‘The impact of changing medicare reimbursement rates on physician‐induced demand’, Medical Care, Vol. 21, pp. 803–815.
Paper not yet in RePEc: Add citation now
Rice, T. H. and Labelle, R. J. (1989). ‘Do physicians induce demand for medical services?’, Journal of Health Politics, Policy and Law, Vol. 14, pp. 587–600.
- Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Epstein, A. M. and Frank, R. G. (2003). Demand effects of recent changes in prescription drug promotion, Forum for Health Economics and Policy, Vol. 6, pp. 1–26.
Paper not yet in RePEc: Add citation now
- Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Frank, R. G. and Epstein, A. M. (2002). ‘Promotion of prescription drugs to consumers’, New England Journal of Medicine, Vol. 346, pp. 498–505.
Paper not yet in RePEc: Add citation now
- Ruhm, C. J. (2018). ‘Corrected US opioid‐involved drug poisoning deaths and mortality rates, 1999–2015’, Addiction, Vol. 113, pp. 1339–1344.
Paper not yet in RePEc: Add citation now
Ruhm, C. J. (2019). ‘Drivers of the fatal drug epidemic’, Journal of Health Economics, Vol. 64, pp. 25–42.
Savych, B., Neumark, D. and Lea, R. (2019). ‘Do opioids help injured workers recover and get back to work? the impact of opioid prescriptions on duration of temporary disability’, Industrial Relations: A Journal of Economy and Society, Vol. 58, pp. 549–590.
- Schnell, M. (2017). Physician Behavior in the Presence of a Secondary Market: The Case of Prescription Opioids, Mimeo.
Paper not yet in RePEc: Add citation now
- Sekimoto, M. and Ii, M. (2015). ‘Supplier‐induced demand for chronic disease care in Japan: multilevel analysis of the association between physician density and physician‐patient encounter frequency’, Value in Health Regional Issues, Vol. 6, pp. 103–110.
Paper not yet in RePEc: Add citation now
Shigeoka, H. and Fushimi, K. (2014). ‘Supplier‐induced demand for newborn treatment: evidence from Japan’, Journal of Health Economics, Vol. 35, pp. 162–178.
Suppliet, M. (2020). ‘Umbrella branding in pharmaceutical markets’, Journal of Health Economics,Vol. 73,102324.
- U.S. Committee on the Judiciary. (1990). The Licit Importation of Opium: Hearing Before the Subcommittee on Crime of the Committee on the Judiciary, House of Representatives, One Hundred First Congress, Second Session, February 27, 1990, 89, U.S. Government Printing Office, Washington, D.C.
Paper not yet in RePEc: Add citation now
- United Nations. (2003). Limited Opium Yield Assessment Surveys, Office of Drugs and Crime, United Nations Technical Report No. SCITEC/19.
Paper not yet in RePEc: Add citation now
- United Nations. (2005). Report of the International Narcotics Control Board for 2005, International Narcotics Control Board, United Nations Technical Report No. E/INCB/2005/1.
Paper not yet in RePEc: Add citation now
Van Zee, A. (2009). ‘The promotion and marketing of oxycontin: commercial triumph, public health tragedy’, American Journal of Public Health, Vol. 99, pp. 221–227.
- Ventola, C. L. (2011). ‘The drug shortage crisis in the United States: causes, impact, and management strategies’, Pharmacy and Therapeutics, Vol. 36, p. 740.
Paper not yet in RePEc: Add citation now
- Waldman, D. E. and Jensen, E. J. (2001). Industrial Organization: Theory and Practice. Boston: Addison‐Wesley.
Paper not yet in RePEc: Add citation now
- Walid, M. S., Donahue, S. N., Darmohray, D. M., Hyer, L. A., Jr. and Robinson, J. S., Jr. (2008). ‘The fifth vital sign: what does it mean?’, Pain Practice, Vol. 8, pp. 417–422.
Paper not yet in RePEc: Add citation now
- Zejcirovic, D. and Fernandez, F. (2018). Can Pharmaceutical Promotion to Physicians lead to Adverse Health Outcomes? Evidence from the Opioid Epidemic in the US, Mimeo.
Paper not yet in RePEc: Add citation now